Which of the following combination therapies is supported by evidence for tobacco cessation?

The combination of bupropion SR and a nicotine patch is supported by evidence for tobacco cessation because both components function synergistically to enhance quitting success. Bupropion SR is an antidepressant that has been found to effectively reduce cravings and withdrawal symptoms associated with nicotine dependence. It works on neurotransmitters in the brain that are involved in addiction and can help to diminish the urge to smoke.

On the other hand, the nicotine patch provides a steady dose of nicotine to the bloodstream, which helps to ease withdrawal symptoms and reduces the physical cravings for tobacco. By combining these two methods, individuals can benefit from both the pharmacological support that addresses mental cravings and emotional aspects of smoking, as well as the physical need for nicotine that the patch supplies. Research has shown that this combination can improve the likelihood of successful smoking cessation compared to using either treatment alone.

Other options do not have the same level of evidence supporting their effectiveness as combination therapies for smoking cessation. This highlights the importance of using proven methods in tobacco addiction treatment to maximize the chances of quitting.